Mpox clinical trials at University of California Health

1 research study open to eligible people

Tecovirimat for Human Mpox Virus
open to all eligible people
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
at UC Davis UCLA UCSD UCSF

Last updated: July 11, 2024